共查询到20条相似文献,搜索用时 78 毫秒
1.
Cotyledons of tomato seedlings that germinated in a 20 µM AlK(SO4)2 solution remained chlorotic while those germinated in an aluminum free medium were normal (green) in color. Previously, we have reported the effect of aluminum toxicity on root proteome in tomato seedlings (Zhou et al.1). Two dimensional DIGE protein analysis demonstrated that Al stress affected three major processes in the chlorotic cotyledons: antioxidant and detoxification metabolism (induced), glyoxylate and glycolytic processes (enhanced), and the photosynthetic and carbon fixation machinery (suppressed).Key words: aluminum, cotyledons, proteome, tomatoDifferent biochemical processes occur depending on the developmental stages of cotyledons. During early seed germination, before the greening of the cotyledons, glyoxysomes enzymes are very active. Fatty acids are converted to glucose via the gluconeogenesis pathway.2,3 In greening cotyledons, chloroplast proteins for photosynthesis and leaf peroxisomal enzymes in the glycolate pathway for photorespiration are metabolized.2–4 Enzymes involved in regulatory mechanisms such as protein kinases, protein phosphatases, and mitochondrial enzymes are highly expressed.3,5,6The chlorotic cotyledons are similar to other chlorotic counterparts in that both contains lower levels of chlorophyll, thus the photosynthetic activities are not as active. In order to understand the impact of Al on tomato cotyledon development, a comparative proteome analysis was performed using 2D-DIGE following the as previously described procedure.1 Some proteins accumulated differentially in Al-treated (chlorotic) and untreated cotyledons (Fig. 1). Mass spectrometry of tryptic digestion fragments of the proteins followed by database search has identified some of the differentially expressed proteins (Open in a separate windowFigure 1Image of protein spots generated by Samspot analysis of Al treated and untreated tomato cotyledons proteomes separated on 2D-DIGE.
Open in a separate window 相似文献
Table 1
Proteins identified from tomato cotyledons of seeds germinating in Al-solutionSpot No. | Fold (treated/ctr) | ANOVA (p value) | Annotation | SGN accession |
1 | 2.34 | 0.001374 | 12S seed storages protein (CRA1) | SGN-U314355 |
2 | 2.13 | 0.003651 | unidentified | |
3 | 2.0 | 0.006353 | lipase class 3 family | SGN-U312972 |
4 | 1.96 | 0.002351 | large subunit of RUBISCO | SGN-U346314 |
5 | 1.95 | 2.66E-05 | arginine-tRNA ligase | SGN-U316216 |
6 | 1.95 | 0.003343 | unidentified | |
7 | 1.78 | 0.009219 | Monodehydroascorbate reductase (NADH) | SGN-U315877 |
8 | 1.78 | 0.000343 | unidentified | |
9 | 1.75 | 4.67E-05 | unidentified | |
12 | 1.70 | 0.002093 | unidentified | |
13 | 1.68 | 0.004522 | unidentified | |
15 | 1.66 | 0.019437 | Glutamate dehydrogenase 1 | SGN-U312368 |
16 | 1.66 | 0.027183 | unidentified | |
17 | 1.62 | 2.01E-08 | Major latex protein-related, pathogenesis-related | SGN-U312368 |
18 | −1.61 | 0.009019 | RUBisCo activase | SGN-U312543 |
19 | 1.61 | 0.003876 | Cupin family protein | SGN-U312537 |
20 | 1.60 | 0.000376 | unidentified | |
22 | 1.59 | 0.037216 | unidentified | |
0.003147 | unidentified | |||
29 | −1.56 | 0.001267 | RUBisCo activase | SGN-U312543 |
35 | 1.52 | 0.001955 | unidentified | |
40 | 1.47 | 0.007025 | unidentified | |
41 | 1.47 | 0.009446 | unidentified | |
45 | 1.45 | 0.001134 | unidentified | |
59 | −1.40 | 5.91E-05 | 12 S seed storage protein | SGN-U314355 |
61 | 1.39 | 1.96E-05 | MD-2-related lipid recognition domain containing protein | SGN-U312452 |
65 | 1.37 | 0.000608 | triosephosphate isomerase, cytosolic | SGN-U312988 |
68 | 1.36 | 0.004225 | unidentified | |
81 | 1.32 | 0.001128 | unidentified | |
82 | −1.31 | 0.001408 | 33 kDa precursor protein of oxygen-evolving complex | SGN-U312530 |
87 | 1.30 | 0.002306 | unidentified | |
89 | −1.3 | 0.000765 | unidentified | |
92 | 1.29 | 0.000125 | superoxide dismutase | SGN-U314405 |
98 | 1.28 | 0.000246 | triosephosphate isomerase, cytosolic | SGN-U312988 |
2.
Fengzhen Yang Qi Zhao Lipeng Wang Jinying Wu Lihua Jiang Li Sheng Leyan Zhang Zhaoping Xue Maoli Yi 《Polish journal of microbiology》2022,71(2):251
Cefoperazone/sulbactam (CSL) and piperacillin/tazobactam (TZP) are commonly used in clinical practice in China because of their excellent antimicrobial activity. CSL and TZP-nonsusceptible Enterobacteriaceae are typically resistant to extended-spectrum cephalosporins such as ceftriaxone (CRO). However, 11 nonrepetitive Enterobacteriaceae strains, which were resistant to CSL and TZP yet susceptible to CRO, were collected from January to December 2020. Antibiotic susceptibility tests and whole-genome sequencing were conducted to elucidate the mechanism for this rare phenotype. Antibiotic susceptibility tests showed that all isolates were amoxicillin/clavulanic-acid resistant and sensitive to ceftazidime, cefepime, cefepime/tazobactam, cefepime/zidebactam, ceftazidime/avibactam, and ceftolozane/tazobactam. Whole-genome sequencing revealed three of seven Klebsiella pneumoniae strains harbored blaSHV-1 only, and four harbored blaSHV-1 and blaTEM-1B. Two Escherichia coli strains carried blaTEM-1B only, while two Klebsiella oxytoca isolates harbored blaOXY-1-3 and blaOXY-1-1, respectively. No mutation in the β-lactamase gene and promoter sequence was found. Outer membrane protein (Omp) gene detection revealed that numerous missense mutations of OmpK36 and OmpK37 were found in all strains of K. pneumoniae. Numerous missense mutations of OmpK36 and OmpK35 and OmpK37 deficiency were found in one K. oxytoca strain, and no OmpK gene was found in the other. No Omp mutations were found in E. coli isolates. These results indicated that narrow spectrum β-lactamases, TEM-1, SHV-1, and OXY-1, alone or in combination with Omp mutation, contributed to the resistance to CSL and TZP in CRO-susceptible Enterobacteriaceae.Antibiotic susceptibility tests
Open in a separate windowCROceftriaxone, CAZceftazidime, FEPcefepime, AMC:amoxicillin clavulanic-acid, CSLcefoperazone/sulbactam, TZP:piperadllin/tazobactam, FPT:cefepime tazobactam, FPZ:cefepime/zidebactam, CZA:ceftazidime/avibactam, CZTceftolozane/tazobactam Gene sequencing results
Open in a separate window 相似文献
Antibiotics | Breakpoint, (μg/ml) | Klebsiella pneumoniae | Escherichia cou | Klebriehd axyoca | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
E1 | E3 | E4 | E7 | E9 | E10 | E11 | E6 | E8 | E2 | E5 | ||
CRO | ≤1≥4 | ≤0.5 | ≤0.5 | ≤0.5 | ≤0.5 1 | ≤0.5 | 1 | ≤0.5 | ≤0.5 | 1 | 1 | |
CAZ | 4 ≥16 | 1 | 2 | 1 | 4 | 4 | 4 | 4 | 2 | 4 | 1 1 | |
FEP | ≤2 216 1 | 1 | 0.25 | 1 | 2 | 2 | 2 | 0.5 | 2 | 1 1 | ||
AMC | ≤8 ≥32 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 | ≥128 |
CSL | ≤16 ≥64 | 64 | 64 | 64 | 64 | ≥128 | 128 | ≥128 | 64 | 128 | 128 | ≥128 |
TZP | ≤16 ≥128 | ≥256 | ≥256 | ≥256 | ≥256 | 2256 | 2256 | ≥256 | ≥256 | ≥256 | ≥256 | ≥256 |
FPT | ≤2 ≥16 | 1 | 0.5 | 0.06 | 0.125 | 2 | 1 | 2 | 0.25 | 1 | 0.125 | 0.25 |
FPZ | ≤2 216 | 0.25 | 0.25 | 0.06 | 0.125 | 0.25 | 0.25 1 | 0.125 | 0.25 | 0.125 | 0.125 | |
CZA | ≤8 216 1 | 0.5 | 0.25 | 0.25 | 1 | 0.25 | 1 | 0.5 | 0.5 | 0.5 | 0.25 | |
CZT | ≤2 28 | 2 | 1 | 0.5 1 | 2 | 2 | 2 1 | 1 | 2 | 2 |
Number | Strain | ST | p-Lactamase gene | Promoter sequence mutation | Omp mutation |
---|---|---|---|---|---|
El | Kpn | 45 | blaSHV-1, blaTEM-lB | none | OmpK36, OmpK3 7 |
E3 | Kpn | 45 | blaSHV-1, blaTEM-lB | none | OmpK36. OmpK3 7 |
E4 | Kpn | 2854 | blaSHV-1 | none | OmpK36, OmpK3 7 |
E7 | Kpn | 2358 | blaSHV-1 - blaTEM-lB | none | OmpK36, OmpK3 7 |
E9 | Kpn | 2358 | blaSHV-1. blaTEM-lB | none | OmpK36. OmpK3 7 |
E10 | Kpn 18 | 9 | blaSHV-1 | none | OmpK36. OmpK3 7 |
Ell | Kpn | 45 | blaSHV-1 | none | OmpK36, OmpK3 7 |
E6 | Eco | 88 | blaTEM-lB | none | none |
ES | Eco | 409 | blaTEM-1B | none | none |
E2 | Kox | 194 | blaOXY-1-3 | none | OmpK36 mutations. OmpK35 and OmpK 37 deficiency |
E5 | Kox 11 | blaOXY-1-1 | none | no OmpK (OmpK3 5, OmpK36 and OmpK37) gene found |
3.
4.
Hennie G Raterman Alexandre E Voskuyl Ben AC Dijkmans Michael T Nurmohamed 《Arthritis research & therapy》2009,11(5):413-2
With great interest, we read the article by Toms and colleagues [1] in the previous issue of Arthritis Research & Therapy, in which they assessed prevalences of metabolic syndrome (MetS) in rheumatoid arthritis (RA) patients. Moreover, they identified demographic and clinical factors that may be associated with MetS. Toms and colleagues found prevalences of up to 45% of MetS and demonstrated older age and health status (health assessment questionnaire) to be associated with MetS irrespectively of the definition used. Of most interest, an association between methotrexate (MTX) use and decreased presence of MetS was observed in patients more than 60 years of age. The investigators hypothesized that this may be attributed to a drug-specific effect (and not to an anti-inflammatory effect) either by changing levels of adenosine, which is known to interact with glucose and lipid metabolism, or by an indirect effect mediated through concomitant folic acid administration, thereby decreasing homocysteine levels.Recently, we also examined the prevalence of MetS in (a subgroup of) RA patients in the CARRÉ investigation, a prospective cohort study on prevalent and incident cardiovascular disease and its underlying cardiovascular risk factors [2]. The findings of Toms and colleagues stimulated us to perform additional analyses in our total study population (n = 353).The prevalences of MetS were 35% and 25% (Table (Table1)1) according to criteria of National Cholesterol Education Program (NCEP) 2004 and NCEP 2001, respectively. In multivariate backward regression analyses, we found significant associations between body mass index, pulse rate, creatinine levels, hypothyroidism and diabetes mellitus and the presence of MetS independently of the criteria used (Table (Table2).2). However, an independent association between single use of MTX or use of MTX in combination with other disease-modifying antirheumatic drugs, on the one hand, and a decreased prevalence of MetS, on the other hand, could not be demonstrated (even in the subgroup of patients over the age of 60).
Open in a separate windowaMetabolic syndrome (MetS) according to National Cholesterol Education Program (NCEP) 2001; bMetS according to NCEP 2004. Continuous variables are presented as means (± standard deviations) in cases of normal distribution or as medians (interquartile ranges) in cases of non-normal distribution. BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; MTX, methotrexate; RA, rheumatoid arthritis; SSZ, sulfasalazine; TNF, tumour necrosis factor.
Open in a separate windowaIn multivariate analyses, the following variables were used: gender, age, prednisolone only, methotrexate only, sulfasalazine only, hydroxychloroquine only, tumour necrosis factor-blocking agents, combination of disease-modifying antirheumatic drugs, pack-years, smoking, erosions, DAS28 (disease activity score using 28 joint counts), body mass index, pulse rate, creatinine levels, renal clearance, hypothyroidism and diabetes mellitus. CI, confidence interval; OR, odds ratio.Therefore, to get more support for a drug-specific effect, it is of interest to know whether or not in the study of Toms and colleagues the MTX effect was present only in the group of RA patients with single use of MTX or in the group of MTX-treated patients with other antirheumatic drugs. As patients with MetS were significantly older, it would give further information whether age was an independent risk factor for MetS in regression analyses. Moreover, as readers, we are not informed about comorbidities like diabetes and clinical hypothyroidism, which are notorious cardiometabolic risk factors. On the whole, we could not confirm a plausible protective role for the use of MTX and presence of MetS, and hence further investigation is required to explain the discrepancy between our findings and those of Toms and colleagues. 相似文献
Table 1
Characteristics of the study populationMetS presenta | MetS absenta | MetS presentb | MetS absentb | |||
---|---|---|---|---|---|---|
n = 84 | n = 265 | n = 121 | n = 228 | P valuea | P valueb | |
Demographics | ||||||
Age, years | 63.8 (± 8) | 63.1 (± 7) | 64.3 (± 8) | 62.7 (± 7) | 0.46 | 0.045 |
Female, percentage | 76 | 63 | 74 | 62 | 0.022 | 0.028 |
RA-related characteristics | ||||||
DAS28 | 4.2 (± 1.3) | 3.9 (± 1.4) | 4.1 (± 1.3) | 3.8 (± 1.4) | 0.21 | 0.062 |
ESR, mm/hour | 22 (10-35) | 16 (9-30) | 20 (10-34) | 17 (9-31) | 0.059 | 0.33 |
CRP, mg/L | 11 (4-21) | 6 (3-16) | 8 (3-18) | 6 (3-19) | 0.021 | 0.46 |
RA duration, years | 7 (4-10) | 7 (4-10) | 7 (4-10) | 7 (5-10) | 0.83 | 0.19 |
Erosion, percentage | 77 | 83 | 79 | 83 | 0.20 | 0.36 |
Number of DMARDs | 1 (1-2) | 1 (1-1) | 1 (1-2) | 1 (1-1) | 0.26 | 0.43 |
MTX current, percentage | 62 | 60 | 63 | 59 | 0.71 | 0.46 |
MTX only, percentage | 39 | 39 | 41 | 38 | 0.95 | 0.67 |
SSZ only, percentage | 8 | 13 | 9 | 14 | 0.23 | 0.22 |
HCQ only, percentage | 1 | 4 | 3 | 4 | 0.31 | 0.55 |
Combination of DMARDs, percentage | 31 | 25 | 29 | 25 | 0.24 | 0.38 |
TNF-blocking agent, percentage | 11 | 9 | 11 | 9 | 0.73 | 0.65 |
Prednisolone only, percentage | 1 | 2 | 3 | 1 | 1.00 | 0.42 |
Cardiovascular risk factors | ||||||
Current smoker, percentage | 26 | 31 | 25 | 32 | 0.42 | 0.15 |
Pack-years, years | 17 (0-34) | 19 (2-38) | 19 (0-35) | 18 (2-38) | 0.23 | 0.75 |
BMI, kg/m2 | 30 (± 4) | 26 (± 5) | 29 (± 4) | 25 (± 5) | < 0.001 | < 0.001 |
Creatinine, μmol/L | 89 (± 21) | 89 (± 16) | 91 (± 22) | 87 (± 14) | 0.99 | 0.070 |
Renal clearance, mL/minute | 81 (± 24) | 72 (± 19) | 77 (± 23) | 73 (± 19) | 0.003 | 0.062 |
Pulse, beats per minute | 76 (± 11) | 73 (± 9) | 75 (± 11) | 73 (± 9) | 0.005 | 0.015 |
Diabetes mellitus, percentage | 14 | 3 | 12 | 3 | < 0.001 | 0.001 |
Hypothyroidism, percentage | 12 | 2 | 9 | 2 | 0.001 | 0.003 |
Table 2
Variables associated with metabolic syndromeUnivariate | Multivariatea | |||||
---|---|---|---|---|---|---|
OR | 95% CI | P value | OR | 95% CI | P value | |
Body mass index | 1.2 | 1.1-1.3 | < 0.001 | 1.2 | 1.1-1.3 | < 0.001 |
Pulse | 1.03 | 1.01-1.06 | 0.011 | 1.03 | 1.00-1.06 | 0.020 |
Creatinine | 1.01 | 1.00-1.02 | 0.080 | 1.02 | 1.00-1.03 | 0.017 |
Hypothyroidism | 4.5 | 1.5-13.2 | 0.007 | 4.7 | 1.5-15.0 | 0.009 |
Diabetes mellitus | 4.8 | 1.8-12.9 | 0.002 | 4.5 | 1.4-15.2 | 0.014 |
5.
Allelic frequency and genotypes of prion protein at codon 136 and 171 in Iranian Ghezel sheep breeds
Siamak Salami Reza Ashrafi Zadeh Mir Davood Omrani Fatemeh Ramezani Amir Amniattalab 《朊病毒》2011,5(3):228-231
PrP genotypes at codons 136 and 171 in 120 Iranian Ghezel sheep breeds were studied using allele-specific PCR amplification and compared with the well-known sheep breeds in North America, the United States and Europe. The frequency of V allele and VV genotype at codon 136 of Ghezel sheep breed was significantly lower than AA and AV. At codon 171, the frequency of allele H was significantly lower than Q and R. Despite the similarities of PrP genotypes at codons 136 and 171 between Iranian Ghezel sheep breeds and some of the studied breeds, significant differences were found with others. Planning of effective breeding control and successful eradication of susceptible genotypes in Iranian Ghezel sheep breeds will not be possible unless the susceptibility of various genotypes in Ghezel sheep breeds to natural or experimental scrapie has been elucidated.Key words: scrapie, Ghezel sheep breed, PrP genotyping, allele specific amplification, codon 136, codon 171Scrapie was first described in England in 1732,1 and it is an infectious neurodegenerative fatal disease of sheep and goats belonging to the group of transmissible subacute spongiform encephalopathies (TSEs), along with bovine spongiform encephalopathy (BSE), chronic wasting disease and Creutzfeldt-Jakob disease.2,3 The term prion, proteinaceous infectious particles, coined by Stanley B. Prusiner, was introduced, and he presents the idea that the causal agent is a protein.4 Prion proteins are discovered in two forms, the wild-type form (PrPc) and the mutant form (PrPSc).5 Although scrapie is an infectious disease, the susceptibility of sheep is influenced by genotypes of the prion protein (PrP) gene.2,6 Researchers have found that the PrP allelic variant alanine/arginine/arginine (ARR) at codons 136, 154 and 171 is associated with resistance to scrapie in several breeds.7–14 Most of the sheep populations in the Near East and North African Region (84% of the total population of 255 million) are raised in Iran, Turkey, Pakistan, Sudan, Algeria, Morocco, Afghanistan, Syria and Somalia.15 In 2003, the Iranian sheep population was estimated at 54,000,000 head. The Ghezel sheep breed, which also is known as Kizil-Karaman, Mor-Karaman, Dugli, Erzurum, Chacra, Chagra, Chakra, Gesel, Gezel, Kazil, Khezel, Khizel, Kizil, Qezel, Qizil and Turkish Brown, originated in northwestern Iran and northeastern Turkey. By considering sheep breeds as one of the main sources of meat, dairy products and related products, a global screening attempt is started in different areas. In compliance with European Union Decision 2003/100/EC, each member state has introduced a breeding program to select for resistance to TSEs in sheep populations to increase the frequency of the ARR allele. A similar breeding program is established in United States and Canada. The Near East and North African Region still needs additional programs to help the global plan of eradication of scrapie-susceptible genotypes. The current study was the first to assess the geographical and molecular variation of codons 136 and 171 polymorphism between Iranian Ghezel sheep breed and well-known sheep breeds.Polymorphism at codon 136 is associated with susceptibility to scrapie in both experimental and natural models.10,11,13,16 17 and Austrian Carynthian sheep.18 Swiss White Alpine showed higher frequency of allele V at position 136 than Swiss Oxford Down, Swiss Black-Brown Mountain and Valais Blacknose.19 Comparison of polymorphism at codon 136 in the current study with some of other breeds (20 some flock of Hampshire sheep21 with current study, but the frequency of it is higher than that of some other breeds.
Open in a separate windowIt has been found that a polymorphism at codon 171 also is associated with susceptibility to experimental scrapie in Cheviot sheep16 and natural scrapie in Suffolk sheep.22 As shown in 23 They also found that different breeds show different predominant genotypes in ewes and rams.23 Different PrP genotypes were found at codon 171 in Austrian sheep breeds, but QQ has higher frequency than others.18 In some kinds of Swiss breeds, allelic frequencies of allele Q was higher than R.19 Distribution of prion protein codon 171 genotypes in Hampshire sheep revealed that different flocks shows different patterns.21 The frequency of PrP genotypes at codon 171 in Iranian Ghezel breeds was similar to some sheep breeds, like the Suffolk breed of Oklahoma sheep, but it was completely different from others (PrP genotypes at codon 172 Breed Allelic frequency Genotypes Reference Q R H RR QR QQ QH RH HH Iranian Iranian Ghezel breeds (n = 120) 55.00 43.33 1.67 23.33 36.67 36.67 0.00 3.33 0.00 Current study Oklahoma sheep (n = 334) De Silva, et al.20 Suffolk 40.95 59.05 0.00 37.07 43.97 18.97 0.00 0.00 0.00 Hampshire 51.89 48.11 0.00 21.70 52.83 25.47 0.00 0.00 0.00 Dorset 67.75 31.25 0.00 7.95 46.59 45.45 0.00 0.00 0.00 Montadale 62.96 37.04 0.00 14.81 44.44 40.74 0.00 0.00 0.00 Hampshire (n = 201) 72.14 26.60 1.26 5.00 42.00 50.00 2.00 1.00 0.00 Youngs, et al.21 German Sheep Breeds (n = 660) Kutzer, et al.28 Bleu du Maine 37.8 62.2 0.00 46.96 30.44 22.6 0.00 0.00 0.00 Friesian Milk S. 90.45 8.9 0.65 1.27 15.3 82.8 0.00 0.00 0.64 Nolana 42.3 57.8 0.00 36.62 42.26 21.13 0.00 0.00 0.00 Suffolk 68.4 27.6 4.0 16.1 21.84 55.17 4.6 1.15 1.15 Texel 55.35 29.7 14.9 12.56 26.83 36.36 11.25 7.36 5.63 Swiss Sheep (n = 200) Gmur, et al.19 Swiss Oxford Down 32.00 68.00 - - - - - - - Swiss Black-Brown M. 70.00 30.00 - - - - - - - Valais Blacknose 85.00 15.00 - - - - - - - Swiss White Alpine 27.00 73.00 - - - - - - - Austrian Sheep (n = 112) Sipos, et al.18 Tyrolean mountain sheep 74.30 25.80 0.00 2.90 45.70 51.40 0.00 0.00 0.00 Forest sheep 77.00 19.20 3.80 11.50 15.40 69.20 0.00 0.00 3.80 Tyrolean stone sheep 81.50 14.80 3.70 0.00 29.60 62.90 7.40 0.00 0.00 Carynthian sheep 72.80 23.00 4.20 4.20 41.70 13.00 8.40 0.00 0.00
Table 1
Comparison of PrP allelic and genotype frequencies at codon 136 in different breedsBreed | A (%) | V (%) | AA (%) | AV (%) | VV (%) | Reference |
Iranian Ghezel breeds (n = 120) | 77.50 | 22.5 | 65.00 | 25.00 | 10.00 | Current study |
Oklahoma sheep (n = 334) | De Silva, et al.27 | |||||
Suffolk | 99.24 | 0.76 | 98.48 | 1.52 | 0.00 | |
Hampshire | 100 | 0.00 | 100 | 0.00 | 0.00 | |
Dorset | 92.6 | 7.94 | 87.30 | 9.52 | 3.17 | |
Montadale | 77.66 | 22.34 | 59.57 | 36.17 | 4.26 | |
Hampshire (n = 48) | 93.75 | 6.25 | 88.00 | 12.00 | 0.00 | Youngs, et al.21 |
German Sheep Breeds (n = 660) | 92.89 | 7.11 | 87.80 | 10.47 | 1.73 | Kutzer, et al.28 |
Bleu du Maine | 83.47 | 16.53 | 69.56 | 27.83 | 2.61 | |
Friesian Milk S. | 100 | 0.00 | 100 | 0.00 | 0.00 | |
Nolana | 90.13 | 9.87 | 85.90 | 8.46 | 5.64 | |
Suffolk | 100 | 0.00 | 100 | 0.00 | 0.00 | |
Texel | 90.87 | 9.13 | 82.16 | 17.41 | 0.43 | |
Swiss Sheep (n = 200) | 92.5 | 7.5 | Gmur, et al.19 | |||
Swiss Oxford Down | 93.00 | 7.00 | - | - | - | |
Swiss Black-Brown M. | 99.00 | 1.00 | - | - | - | |
Valais Blacknose | 100 | 0.00 | - | - | - | |
Swiss White Alpine | 88.00 | 22.00 | - | - | - | |
Austrian Sheep (n = 112) | 98.95 | 1.05 | 98.95 | 0.00 | 1.05 | Sipos, et al.18 |
Tyrolean mountain sheep | 100 | 0.00 | 100 | 0.00 | 0.00 | |
Forest sheep | 100 | 0.00 | 100 | 0.00 | 0.00 | |
Tyrolean stone sheep | 100 | 0.00 | 100 | 0.00 | 0.00 | |
Carynthian sheep | 95.80 | 4.20 | 95.80 | 0.00 | 4.20 |